Payment overview · 2025
General Payments
$758.74
24 reported records · 10 companies
Healthcare provider profile · identity verified
Mark Prebonich, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PORT CHARLOTTE, FL · NPI 1912094442
Verified facts
What the public records show
CMS Open Payments records show Mark Prebonich, M.D. received $758.74 in general payments during 2025 across 24 reported records.
Insmed, Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $194.83 | 25.7% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $175.16 | 23.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $102.04 | 13.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.63 | 11.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.65 | 5.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $40.36 | 5.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $34.17 | 4.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.47 | 4.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.99 | 4.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.44 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $742.75 | 23 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $194.83 | 6 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $175.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.03 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.02 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $40.36 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 786 | 360 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 247 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 187 |
| Losartan Potassium | Losartan Potassium | 442 | 199 |
| Metoprolol Succinate | Metoprolol Succinate | 421 | 182 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 372 | 174 |
| Lisinopril | Lisinopril | 361 | 156 |
| Omeprazole | Omeprazole | 263 | 118 |
| Pravastatin Sodium | Pravastatin Sodium | 244 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 88 |
| Metformin Hcl | Metformin Hcl | 210 | 89 |
| Simvastatin | Simvastatin | 207 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 82 |
| Gabapentin | Gabapentin | 173 | 67 |
| Furosemide | Furosemide | 164 | 68 |
| Metformin Hcl Er | Metformin Hcl | 162 | 78 |
| Eliquis | Apixaban | 139 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 70 |
| Sertraline Hcl | Sertraline Hcl | 131 | 65 |
| Alprazolam | Alprazolam | 128 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 38 |
| Ezetimibe | Ezetimibe | 101 | 39 |
| Trazodone Hcl | Trazodone Hcl | 101 | 53 |
| Allopurinol | Allopurinol | 100 | 52 |
| Alendronate Sodium | Alendronate Sodium | 97 | 47 |
| Potassium Chloride | Potassium Chloride | 90 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 45 |
| Mounjaro | Tirzepatide | 74 | 19 |
| Finasteride | Finasteride | 72 | 31 |
| Atenolol | Atenolol | 71 | 33 |
| Donepezil Hcl | Donepezil Hcl | 69 | 25 |
| Tramadol Hcl | Tramadol Hcl | 63 | 12 |
| Glimepiride | Glimepiride | 61 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 24 |
| Ozempic | Semaglutide | 57 | 18 |
| Montelukast Sodium | Montelukast Sodium | 56 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 19 |
| Spironolactone | Spironolactone | 54 | 25 |
| Xarelto | Rivaroxaban | 54 | 18 |
| Famotidine | Famotidine | 53 | 21 |
| Memantine Hcl | Memantine Hcl | 52 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 28 |
| Jardiance | Empagliflozin | 50 | 24 |
| Mirtazapine | Mirtazapine | 48 | 24 |
| Meclizine Hcl | Meclizine Hcl | 44 | 15 |
| Valsartan | Valsartan | 44 | 17 |
| Bupropion Xl | Bupropion Hcl | 43 | 20 |
| Carvedilol | Carvedilol | 43 | 18 |
| Prednisone | Prednisone | 43 | 30 |
| Synthroid | Levothyroxine Sodium | 43 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 19 |
| Meloxicam | Meloxicam | 34 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 13 |
| Warfarin Sodium | Warfarin Sodium | 33 | 14 |
| Celecoxib | Celecoxib | 32 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | 14 |
| Benazepril Hcl | Benazepril Hcl | 30 | 13 |
| Glipizide Er | Glipizide | 30 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 21 |
| Estradiol | Estradiol | 29 | 12 |
| Irbesartan | Irbesartan | 28 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 28 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | 11 |
| Pregabalin | Pregabalin | 27 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | 11 |
| Doxepin Hcl | Doxepin Hcl | 26 | 17 |
| Lorazepam | Lorazepam | 26 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | 12 |
| Methylprednisolone | Methylprednisolone | 25 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | 11 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | 12 |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Torsemide | Torsemide | 21 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 14 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.74 · 24 records | Insmed, Inc. | Arikayce, BREZTRI, Cologuard Collection Kit, FARXIGA, GEMTESA, KEVEYIS, Leqembi, MITRACLIP, QULIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error